Major Depressive Disorder

A pattern of poor sleep could lead to worsened psychiatric wellbeing—and eventually, memory loss.

In a new study, investigators examine the efficacy and tolerability of antipsychotic medications for patients in remission for psychotic depression.

In an extensive population-based study, investigators link children with IBD with an increased risk of any psychiatric disorder.

The association of depression symptoms with cognition and cortical amyloid measurements could lead to better therapies to prevent Alzheimer disease.

In a new multivariable regression study, investigators link depression with a lack of social support and increased IBD activity.

This week's #DocTalk tweet chat generated discussion on the means by which healthcare professionals can influence mental health policies and understanding.

A conventional mass-univariate fMRI analysis helps determine patients that exhibit greater pretreatment neural activity.

New research shows esketamine nasal spray could help treat patients who do not respond to antidepressants.

New research finds association common sleep disorder present in 14% of suicidal patients with major depressive disorder studied.

Investigators examined more than 3500 adolescents and found associations between computer and social media use, but not video game and television use.

A recent study found that young people with life-limiting conditions had higher prevalence rates of both anxiety and depression.

A recent study found that depression among caregivers was associated with a 73% increased risk of emergency department visits in patients with dementia.

A recent study of more than 50,000 found that antidepressant use could reduce a third of deaths among diabetic patients with depression.

A recent study found that every year of education was equivalent to a 2.5% reduction in risk of heart disease.

A recent study from ADA 2019 found that rates of depression, mental illness, and antidepressant use among diabetes patients have increased significantly from 2010 to 2016.

The nasal spray was shown to reduce relapse in patients who achieved remission or stability after 16 weeks of treatment plus antidepressant.

A study presented at APA 2019 found that esketamine spray to be an effective, fast-acting treatment for people with treatment-resistant depression.

Mental health disorders are highly prevalent in certain patients with COPD—and their effect can limit lung function therapy benefit.

Self-reported vision impairment was associated with a greater risk of developing depression and anxiety symptoms in patients 65 and older.

Patients diagnosed with psoriasis face a nearly three-fold greater risk of developing anxiety disorders.

Esketamine nasal spray is currently relegated to a specific depression patient population, but that may not be for long.

From 2010 to 2017, there was an increase of over 30% in the number of commercially insured children being diagnosed with ADHD.

The selective serotonin inverse agonist, previously approved for Parkinson symptoms, could soon seek FDA approval as an adjunctive therapy.

A retroactive review of patients referred to a psychiatric consultant found that most patients left with a different diagnosis.

Pregnant women who suffer from asthma reported a two-fold greater risk for PPD according to the results of a large-scale Quebec hospital cohort.